Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.

Sooraj D, Xu D, Cain JE, Gold DP, Williams BR.

Mol Cancer Ther. 2016 Jul;15(7):1726-39. doi: 10.1158/1535-7163.MCT-15-0890. Epub 2016 Apr 25.

2.

A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.

Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF.

J Immunother. 2010 Feb-Mar;33(2):178-84. doi: 10.1097/CJI.0b013e3181bfcea1.

PMID:
20145546
3.

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.

J Clin Oncol. 2009 Jun 20;27(18):3036-43. doi: 10.1200/JCO.2008.19.8903. Epub 2009 May 4.

4.

Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.

Betting DJ, Mu XY, Kafi K, McDonnel D, Rosas F, Gold DP, Timmerman JM.

Vaccine. 2009 Jan 7;27(2):250-9. doi: 10.1016/j.vaccine.2008.10.055. Epub 2008 Nov 8.

5.

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.

Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF.

J Clin Oncol. 2006 Jul 1;24(19):3107-12. Epub 2006 Jun 5.

PMID:
16754937
6.

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer.

Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD.

J Immunother. 2004 May-Jun;27(3):232-9.

PMID:
15076141
7.

Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.

Shawler DL, Bartholomew RM, Garrett MA, Trauger RJ, Dorigo O, Van Beveren C, Marchese A, Ferre F, Duffy C, Carlo DJ, Sherman LA, Gold DP, Sobol RE.

Clin Exp Immunol. 2002 Jul;129(1):99-106.

9.

Adjuvant immunotherapy is dependent on inducible nitric oxide synthase.

Kahn DA, Archer DC, Gold DP, Kelly CJ.

J Exp Med. 2001 Jun 4;193(11):1261-8.

10.

Preconditioning with fetal cord blood facilitates engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice.

Dialynas DP, Lee MJ, Gold DP, Shao Le, Yu AL, Borowitz MJ, Yu J.

Blood. 2001 May 15;97(10):3218-25.

PMID:
11342452
11.

GM-CSF-independent development of dendritic cells from bone marrow cells in the GM-CSF-receptor-deficient mouse.

Hikino H, Miyagi T, Hua Y, Hirohisa S, Gold DP, Li XK, Fujino M, Tetsuya T, Amemiya H, Suzuki S, Robb L, Miyata M, Kimura H.

Transplant Proc. 2000 Nov;32(7):2458-9. No abstract available.

PMID:
11120243
12.

Cytokine requirement for the development of rat dendritic cells by in vitro culturing of bone marrow cells.

Hua Y, Miyagi T, Saito H, Gold DP, Li XK, Fujino M, Taga T, Amemiya H, Suzuki S, Kokubo T, Kimura H.

Transplant Proc. 2000 Nov;32(7):2078-9. No abstract available.

PMID:
11120075
14.

Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study.

Sobol RE, Shawler DL, Carson C, Van Beveren C, Mercola D, Fakhrai H, Garrett MA, Barone R, Goldfarb P, Bartholomew RM, Brostoff S, Carlo DJ, Royston I, Gold DP.

Clin Cancer Res. 1999 Sep;5(9):2359-65.

15.

A diabetogenic gene prevents T cells from receiving costimulatory signals.

Moore JK, Gold DP, Dreskin SC, Lernmark A, Bellgrau D.

Cell Immunol. 1999 May 25;194(1):90-7.

PMID:
10357884
16.

Nitric oxide in interstitial nephritis and other autoimmune diseases.

Kelly CJ, Gold DP.

Semin Nephrol. 1999 May;19(3):288-95. Review.

PMID:
10226335
17.

Rat NKR-P1+ CD3+ T cells: selective proliferation in interleukin-2, diverse T-cell-receptor-Vbeta repertoire and polarized interferon-gamma expression.

Badovinac V, Boggiano C, Trajković V, Frey AB, Vujanović NL, Gold DP, Mostarica-Stojković M, Vukmanović S.

Immunology. 1998 Sep;95(1):117-25.

18.

An appraisal of T cell subsets and the potential for autoimmune injury.

Kelly CJ, Frishberg Y, Gold DP.

Kidney Int. 1998 Jun;53(6):1574-84. Review. No abstract available.

19.
20.

Inhibition of inducible nitric oxide synthase intensifies injury and functional deterioration in autoimmune interstitial nephritis.

Gabbai FB, Boggiano C, Peter T, Khang S, Archer C, Gold DP, Kelly CJ.

J Immunol. 1997 Dec 15;159(12):6266-75.

PMID:
9550431
21.

Construction and characterization of retroviral vectors for interleukin-2 gene therapy.

Fakhrai H, Shawler DL, Van Beveren C, Lin H, Dorigo O, Solomon MJ, Gjerset RA, Smith L, Bartholomew RM, Boggiano CA, Gold DP, Sobol RE.

J Immunother. 1997 Nov;20(6):437-48.

PMID:
9409449
22.

Nitric oxide and the immunomodulation of experimental allergic encephalomyelitis.

Gold DP, Schroder K, Powell HC, Kelly CJ.

Eur J Immunol. 1997 Nov;27(11):2863-9.

PMID:
9394811
23.

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide.

Gold DP, Smith RA, Golding AB, Morgan EE, Dafashy T, Nelson J, Smith L, Diveley J, Laxer JA, Richieri SP, Carlo DJ, Brostoff SW, Wilson DB.

J Neuroimmunol. 1997 Jun;76(1-2):29-38.

PMID:
9184630
24.

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations.

Wilson DB, Golding AB, Smith RA, Dafashy T, Nelson J, Smith L, Carlo DJ, Brostoff SW, Gold DP.

J Neuroimmunol. 1997 Jun;76(1-2):15-28.

PMID:
9184629
25.

T-cell receptor peptides as immunotherapy for autoimmune disease.

Gold DP, Shroeder K, Golding A, Brostoff SW, Wilson DB.

Crit Rev Immunol. 1997;17(5-6):507-10. Review.

PMID:
9419437
26.

An exploration of attachment styles and personality traits in caregiving for dementia patients.

Markiewicz D, Reis M, Gold DP.

Int J Aging Hum Dev. 1997;45(2):111-32.

PMID:
9395925
27.

Gene therapy approaches to enhance antitumor immunity.

Shawler DL, Fakhrai H, Van Beveren C, Mercola D, Gold DP, Bartholomew RM, Royston I, Sobol RE.

Adv Pharmacol. 1997;40:309-37. Review. No abstract available.

PMID:
9217929
29.
30.

A longitudinal study of Off-Target Verbosity.

Gold DP, Arbuckle TY.

J Gerontol B Psychol Sci Soc Sci. 1995 Nov;50(6):P307-15.

PMID:
7583810
31.

Restricted T-cell receptor usage in DA rats during early collagen-induced arthritis.

Erlandsson H, Müssener A, Klareskog L, Gold DP.

Ann N Y Acad Sci. 1995 Jul 7;756:225-6. No abstract available.

PMID:
7645840
32.

Structural equation model of intellectual change and continuity and predictors of intelligence in older men.

Gold DP, Andres D, Etezadi J, Arbuckle T, Schwartzman A, Chaikelson J.

Psychol Aging. 1995 Jun;10(2):294-303. Erratum in: Psychol Aging 1998 Sep;13(3):434.

PMID:
7662188
33.

Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study.

Sobol RE, Royston I, Fakhrai H, Shawler DL, Carson C, Dorigo O, Gjerset R, Gold DP, Koziol J, Mercola D, et al.

Hum Gene Ther. 1995 Feb;6(2):195-204. No abstract available.

PMID:
7734519
34.

T cells from BB-DP rats show a unique cytokine mRNA profile associated with the IDDM1 susceptibility gene, Lyp.

Gold DP, Shaikewitz ST, Mueller D, Redd JR, Sellins KS, Pettersson A, Lernmark A, Bellgrau D.

Autoimmunity. 1995;22(3):149-61.

PMID:
8734569
35.

Caregiving and dementia: predicting negative and positive outcomes for caregivers.

Gold DP, Cohen C, Shulman K, Zucchero C, Andres D, Etezadi J.

Int J Aging Hum Dev. 1995;41(3):183-201.

PMID:
8666465
36.

When home caregiving ends: a longitudinal study of outcomes for caregivers of relatives with dementia.

Gold DP, Reis MF, Markiewicz D, Andres D.

J Am Geriatr Soc. 1995 Jan;43(1):10-6.

PMID:
7806732
37.

TCR V gene usage in autoimmunity.

Gold DP.

Curr Opin Immunol. 1994 Dec;6(6):907-12. Review.

PMID:
7536011
38.

Restricted T cell receptor usage in DA rats during early collagen-induced arthritis.

Erlandsson H, Müssener A, Klareskog L, Gold DP.

Eur J Immunol. 1994 Aug;24(8):1929-32.

PMID:
8056051
39.

Social drinking and cognitive functioning revisited: the role of intellectual endowment and psychological distress.

Arbuckle TY, Chaikelson JS, Gold DP.

J Stud Alcohol. 1994 May;55(3):352-61.

PMID:
8022184
40.

Measurement of lifetime alcohol consumption.

Chaikelson JS, Arbuckle TY, Lapidus S, Gold DP.

J Stud Alcohol. 1994 Mar;55(2):133-40.

PMID:
8189733
42.
43.

Identification of rat Tcra-V 4 and 8 gene products by monoclonal antibodies and cDNA sequence.

Torres-Nagel NE, Giegerich G, Gold DP, Hünig T.

Immunogenetics. 1994;39(5):367-70. No abstract available.

PMID:
8168856
44.

Personality traits as determinants of burden and health complaints in caregiving.

Reis MF, Gold DP, Andres D, Markiewicz D, Gauthier S.

Int J Aging Hum Dev. 1994;39(3):257-71.

PMID:
7875917
45.

Factors determining the decision to institutionalize dementing individuals: a prospective study.

Cohen CA, Gold DP, Shulman KI, Wortley JT, McDonald G, Wargon M.

Gerontologist. 1993 Dec;33(6):714-20.

PMID:
8314097
46.

Analysis of the rat T-cell receptor repertoire and superantigen reactivity with TCR V-specific monoclonal antibodies.

Torres-Nagel NE, Herrmann T, Gold DP, Hünig T.

Transplant Proc. 1993 Oct;25(5):2778-9. No abstract available.

PMID:
8105578
47.

Aging, inhibition, and verbosity.

Arbuckle TY, Gold DP.

J Gerontol. 1993 Sep;48(5):P225-32.

PMID:
8366267
48.

The V-region disease hypothesis: new evidence suggests it is probably wrong.

Wilson DB, Steinman L, Gold DP.

Immunol Today. 1993 Aug;14(8):376-80; discussion 380-2. Review.

PMID:
7691066
49.

Where, when, and how to detect biased expression of disease-relevant V beta genes in rats with experimental autoimmune encephalomyelitis.

Offner H, Buenafe AC, Vainiene M, Celnik B, Weinberg AD, Gold DP, Hashim G, Vandenbark AA.

J Immunol. 1993 Jul 1;151(1):506-17.

PMID:
7686948
50.

Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis.

Karin N, Szafer F, Mitchell D, Gold DP, Steinman L.

J Immunol. 1993 May 1;150(9):4116-24.

PMID:
8386207

Supplemental Content

Support Center